Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial

  title={Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial},
  author={Panchalee Satpanich and Wanjak Pongsittisak and Siriporn Manavathongchai},
  journal={Clinical Rheumatology},
Objective Currently available guidelines on urate-lowering therapy (ULT) initiation in acute gout flare are conflicting. We compared the time to complete resolution of acute gout flare between early and late allopurinol initiation. Methods This 28-day, randomized controlled, open-label trial included patients with crystal-proven gout who were presented with acute gout flare within 72 h of arthritis onset. Exclusion criteria were advanced renal failure, ongoing ULT, and presence of the HLA-B… 


Does Starting Allopurinol Prolong Acute Treated Gout? A Randomized Clinical Trial
The authors initiated allopurinol at low doses during an acute gout attack in patients who met criteria for starting urate-lowering therapy and did not have abnormal kidney or liver function, and found that the acute phase of pain rapidly improved in both groups.
Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial.
Oral prednisolone and indomethacin had similar analgesic effectiveness among patients with acute gout and is a safe, effective first-line option for treatment of acute g out.
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
It is indicated that starting allopurinol at a dose of 1.5 mg per unit of estimated GFR may be associated with a reduced risk of AHS, and the dose can be gradually increased to achieve the target serum urate level.
Gout: state of the art after a decade of developments
It is emphasized that the current epidemiology of gout indicates a rising prevalence worldwide, not only in Western countries but also in Southeast Asia, in close relationship with the obesity and metabolic syndrome epidemics.
2016 updated EULAR evidence-based recommendations for the management of gout
In addition to education and a non-pharmacological management approach, urate-lowering therapy (ULT) should be considered from the first presentation of the disease, and serum uric acid (SUA) levels should be maintained at the predefined urate target to cure the disease.
Safety and tolerability of available urate-lowering drugs: a critical review
This review will focus on the safety and tolerability profile of the available urate-lowering drugs: xanthine oxidase inhibitors (XOIs), uricosuric agents and injectable uricases.
Ibuprofen in the treatment of acute gouty arthritis.
Ten patients with acute gouty arthritis were treated with daily doses of ibuprofen and all patients had rapid improvement and complete resolution within 72 hours; no adverse reactions were reported.
OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout
To determine the extent to which participants at the Outcome Measures in Rheumatology (OMERACT) 11 meeting agree that instruments used in clinical trials to measure OMERACT core outcome domains in acute gout fulfill O MERACT filter requirements of truth, discrimination, and feasibility, and where future research efforts need to be directed, measures of pain, joint swelling, joint tenderness, and patient global assessment in acute Gout were endorsed.
The British Society for Rheumatology Guideline for the Management of Gout.
Gout is the most common cause of inflammatory arthritis worldwide and is frequently associated with co-morbidities such as obesity, dyslipidaemia, diabetes mellitus, chronic renal insufficiency, hypertension, cardiovascular disease, hypothyroidism, anaemia, psoriasis, chronic pulmonary diseases, depression and OA.